A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System

Osteoporosis International

Volumn 23, Issue 4, 2012, Pages 1415-1424

  Devine, J ^a   Trice, S ^a   Finney, Z ^a   Yarger, S ^a   Nwokeji, E ^a   Linton, A ^a   Davies, W ^b  

^a 4130 Stanley Road   (United States)

^b Office of the Assistant Secretary of Defense (Health Affairs)   (United States)

Author keywords

Adherence; Bisphosphonate; Compliance; Osteoporosis; Persistence

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; IBANDRONIC ACID; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADOLESCENT; ADULT; AGED; ARMY; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; MILITARY MEDICINE; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; STATISTICS; UNITED STATES;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MILITARY MEDICINE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84861734883     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1729-4     Document Type: Article

References (27)

1. Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA (2000) Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 11(5):460-466. doi:10.1007/s001980070115
2. Gabriel SE, Tosteson AN, Leibson CL et al (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13 (4):323-330. doi:10.1007/s001980200033
3. Bluic D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301 (5):513-521. doi:10.1001/jama.2009.50
4. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348(9041):1535-1541. doi:10.1016/S0140-6736(96)07088-2
5. Papapoulos SE (2001) Bisphosphonates in the management of postmenopausal osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. vol. 2, 2nd edn. Academic, San Diego, pp 631-649
6. Compston J (2010) Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 6(2):82-88
7. Solomon DH, Avorn J, Katz J et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165(20):2414-2419
8. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8):1296-1310. doi:10.1016/S0149-2918(01)80109-0
9. Rabenda V, Hiligsmann M, Reginster JY (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10(14):2303-2315. doi:10.1517/14656560903140533
10. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031. doi:10.1007/s00198-006-0322-8
11. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA (2010) Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med 123(3):275-280. doi:10.1016/j. amjmed.2009.05.017
12. Cramer JA, Silverman SL, Gold DT (2007) Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin 23 (10):2369-2377. doi:10.1185/030079907X226311
13. Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11 (1):44-47
14. Peterson AM, Nau DP, Cramer JA et al (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10(1):3-12
15. Weiss TW, Henderson SC, McHorney CA, Cramer JA (2007) Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 23 (9):2193-2203. doi:10.1185/030079907X226069
16. Cooper A, Drake J, Brankin E, PERSIST Investigators (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60(8):896-905. doi:10.1111/j.1742-1241.2006.01059.x
17. Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24(1):37-55
18. Rossini M, Bianchi G, Di Munno O et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17(6):914-921. doi:10.1007/s00198-006-0073-6
19. Sellmeyer DE (2010) Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 304(13):1480-1484. doi:10.1001/jama.2010. 1360
20. Bonnick SL, Silverman S, Tanner SB et al (2009) Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J Wom Health (Larchmt) 18(7):935-943
21. Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22 (1):21-26. doi:10.1007/s00198-010-1274-6
22. Binkley N, Martens MG, Silverman SL et al (2009) Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. SouthMed J 102(5):486-492. doi:10.1097/SMJ.0b013e31819ed0dd
23. Blumentals WA, Harris ST, Cole RE, Huang L, Silverman SL (2009) Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Ann Pharmacother 43(4):577-585. doi:10.1345/aph.1L555
24. Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid IR (2010) Prolonged antiresorptive activity of zolendronate: a randomized, controlled trial. J Bone Miner Res 25(10):2251-2255. doi:10.1002/jbmr.103
25. BologneseMA, Civitelli R, DreznerM, Emkey R (2005) Intravenous ibandronate injections with extended dosing intervals provide at least equivalent efficacy to daily oral ibandronate: 1-year results from the DIVA study. Presented at the Sixth international symposium on osteoporosis: current status and future directions. National Osteoporosis Foundation, Washington DC, April 6. http://nof.confex.com/nof/2005/techprogram/P272.HTM. Accessed 28 Dec 2010
26. Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013-1022. doi:10.4065/81.8.1013
27. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14(12):965-968. doi:10.1007/s00198-003-1502-4